New Developments in Dual-Labeled Molecular Imaging Agents.
J Nucl Med
; 60(4): 459-465, 2019 04.
Article
em En
| MEDLINE
| ID: mdl-30733318
ABSTRACT
Intraoperative detection of tumors has had a profound impact on how cancer surgery is performed and addresses critical unmet needs in surgical oncology. Tumor deposits, margins, and residual cancer can be imaged through the use of fluorescent contrast agents during surgical procedures to complement visual and tactile guidance. The combination of fluorescent and nuclear contrast into a multimodality agent builds on these capabilities by adding quantitative, noninvasive nuclear imaging capabilities to intraoperative imaging. This review focuses on new strategies for the development and evaluation of targeted dual-labeled molecular imaging agents while highlighting the successful first-in-human application of this technique.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imagem Molecular
/
Marcação por Isótopo
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Nucl Med
Ano de publicação:
2019
Tipo de documento:
Article